JPWO2020227691A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020227691A5
JPWO2020227691A5 JP2021566485A JP2021566485A JPWO2020227691A5 JP WO2020227691 A5 JPWO2020227691 A5 JP WO2020227691A5 JP 2021566485 A JP2021566485 A JP 2021566485A JP 2021566485 A JP2021566485 A JP 2021566485A JP WO2020227691 A5 JPWO2020227691 A5 JP WO2020227691A5
Authority
JP
Japan
Prior art keywords
composition
oligonucleotides
c9orf72
m5ceo
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532169A5 (https=
JP2022532169A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032244 external-priority patent/WO2020227691A2/en
Publication of JP2022532169A publication Critical patent/JP2022532169A/ja
Publication of JPWO2020227691A5 publication Critical patent/JPWO2020227691A5/ja
Publication of JP2022532169A5 publication Critical patent/JP2022532169A5/ja
Priority to JP2025037970A priority Critical patent/JP2025125554A/ja
Pending legal-status Critical Current

Links

JP2021566485A 2019-05-09 2020-05-08 オリゴヌクレオチド組成物及びその使用方法 Pending JP2022532169A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025037970A JP2025125554A (ja) 2019-05-09 2025-03-11 オリゴヌクレオチド組成物及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962845765P 2019-05-09 2019-05-09
US62/845,765 2019-05-09
US201962851558P 2019-05-22 2019-05-22
US62/851,558 2019-05-22
US201962911340P 2019-10-06 2019-10-06
US62/911,340 2019-10-06
US202062983736P 2020-03-01 2020-03-01
US62/983,736 2020-03-01
PCT/US2020/032244 WO2020227691A2 (en) 2019-05-09 2020-05-08 Oligonucleotide compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025037970A Division JP2025125554A (ja) 2019-05-09 2025-03-11 オリゴヌクレオチド組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022532169A JP2022532169A (ja) 2022-07-13
JPWO2020227691A5 true JPWO2020227691A5 (https=) 2023-05-16
JP2022532169A5 JP2022532169A5 (https=) 2023-05-16

Family

ID=73051251

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566485A Pending JP2022532169A (ja) 2019-05-09 2020-05-08 オリゴヌクレオチド組成物及びその使用方法
JP2025037970A Pending JP2025125554A (ja) 2019-05-09 2025-03-11 オリゴヌクレオチド組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025037970A Pending JP2025125554A (ja) 2019-05-09 2025-03-11 オリゴヌクレオチド組成物及びその使用方法

Country Status (7)

Country Link
US (1) US20220145300A1 (https=)
EP (1) EP3965780A4 (https=)
JP (2) JP2022532169A (https=)
CN (1) CN114502177A (https=)
AU (1) AU2020267775A1 (https=)
CA (1) CA3139513A1 (https=)
WO (1) WO2020227691A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
CN108135921B (zh) 2015-07-22 2023-10-17 波涛生命科学有限公司 寡核苷酸组合物及其方法
CA3015823A1 (en) 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
MA46905A (fr) 2016-11-23 2019-10-02 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
US11597927B2 (en) 2017-06-02 2023-03-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11718638B2 (en) 2017-06-21 2023-08-08 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
TW201920672A (zh) 2017-08-08 2019-06-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
IL277889B2 (en) 2018-04-12 2025-01-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods of using them
EP3790596A4 (en) 2018-05-11 2022-04-06 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CN113748116A (zh) 2019-03-20 2021-12-03 波涛生命科学有限公司 可用于寡核苷酸制备的技术
KR20220070324A (ko) * 2019-10-06 2022-05-30 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 이용 방법
CA3236136A1 (en) * 2021-10-27 2023-05-04 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
AR131145A1 (es) 2022-11-24 2025-02-19 Proqr Therapeutics Ii Bv Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
CA3276262A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
EP4669753A1 (en) 2023-02-20 2025-12-31 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
AU2024246572A1 (en) 2023-03-27 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025213142A2 (en) * 2024-04-05 2025-10-09 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762326T5 (es) * 2012-10-15 2023-04-27 Ionis Pharmaceuticals Inc Métodos para modular la expresión de C9ORF72
BR112018012894A2 (en) * 2015-12-23 2018-12-04 Crispr Therapeutics Ag Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis and / or Frontotemporal Lobular Degeneration
TW201920672A (zh) * 2017-08-08 2019-06-01 新加坡商波濤生命科學有限公司 寡核苷酸組合物及其使用方法

Similar Documents

Publication Publication Date Title
JPWO2020227691A5 (https=)
JPWO2021071788A5 (https=)
JPWO2021178237A5 (https=)
EP4153604A1 (en) Oligonucleotide compositions and methods thereof
WO2021234459A9 (en) Double stranded oligonucleotide compositions and methods relating thereto
JP2020534253A5 (https=)
JP2023078293A5 (https=)
JP7690979B2 (ja) 一本鎖オリゴヌクレオチド
RU2689548C2 (ru) Лечение рака
EP4022059A1 (en) Oligonucleotide compositions and methods of use thereof
JPWO2022099159A5 (https=)
WO2023049475A1 (en) Oligonucleotide compositions and methods thereof
JPWO2022270585A5 (https=)
JP2026052054A (ja) Calm2のアンチセンスオリゴヌクレオチド
WO2019044974A1 (ja) スモールガイドアンチセンス核酸とその使用
AU2022352668A1 (en) Double stranded oligonucleotide compositions and methods relating thereto
US8247540B2 (en) Caged nucleotides and oligonucleotides and their application
WO2021157730A1 (ja) 核酸医薬とその使用
JP2022523065A (ja) Nr2e3発現抑制オリゴヌクレオチド、それを含む組成物、及びそれらの使用方法
JPWO2020172559A5 (https=)
TW202102516A (zh) 膦醯基乙酸酯間隙子寡核苷酸
WO2025213136A1 (en) Oligonucleotides comprising pn linkages and methods thereof
WO2025160574A1 (en) Oligonucleotide compositions and methods thereof
JPWO2021231606A5 (https=)
CN118680948A (zh) 寡核苷酸及其在抗乙型肝炎病毒中的应用